Marrakech – Moroccan pharmaceutical company Galenica completed its first shipment of medicines to the Russian Federation, in partnership with Asia Pharm Group. The operation marks the Casablanca-based drugmaker’s initial entry into the Eurasian Economic Union market – a trade bloc comprising Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.
Galenica secured both GMP certification and EAC Marketing Authorizations ahead of the shipment. Those regulatory clearances are required to circulate pharmaceutical products across EAEU member states. With them, the company became the first Moroccan, Arab, and African pharmaceutical laboratory to obtain market access authorizations for the bloc.
Its products are now present on the Russian market across several therapeutic categories, including gastroenterology and treatments for cold-related conditions, among other areas.
Alexey Andreev, Russia’s trade representative in Morocco, described the delivery as part of a broader bilateral trajectory. Morocco’s growing pharmaceutical industry, he noted, “opens new perspectives for widening Russo-Moroccan cooperation.”
He pointed to parallel tracks already underway – deliveries of Russian medicines to Morocco and production localization projects within the kingdom – as part of the same dynamic.
“Galenica is the first Moroccan pharmaceutical laboratory to have obtained the authorizations necessary for the circulation of its medicines on the Eurasian Economic Union market,” Andreev remarked.
Conditions are now taking shape, the trade representative indicated, for projects tied to “supplying the Eurasian Economic Union market with Moroccan pharmaceutical products.” Galenica’s shipment to Russia, he added, fits squarely within that framework.
The company characterized the export as the result of a multiyear effort to align its production with international requirements. Founded more than four decades ago, Galenica manufactures a wide range of pharmaceutical products under international quality standards.
In a public statement, the company called the first shipment “the initial materialization of this regulatory success” and the beginning of “a new dynamic of international development.” Galenica also credited Asia Pharm Group for its role in facilitating access to the Russian market.
The regulatory pathway Galenica completed is not limited to Russia. EAC certifications and marketing authorizations grant the company clearance to distribute across all five EAEU member states. That opens a commercial corridor into markets Moroccan pharmaceutical manufacturers have not traditionally served.
Read also: Morocco’s Laprophan Enters Europe with Swiss Drugmaker Rivopharm Acquisition
